<DOC>
	<DOCNO>NCT00769106</DOCNO>
	<brief_summary>Study hypothesis : The recurrence rate HCC patient radical resection 60-70 % . This study base hypothesis CIK treatment could decrease recurrence rate 15 % 20 % . Abstract : This randomize control study . About 200 patient hepatocellular carcinoma underwent radical resection include . The patient randomize group A ( receive CIK treatment ) group B ( regularly follow ) without anti-cancer treatment resection HCC , randomize ratio 1:1 . Study treatment : Patients group A receive 4 cycle CIK treatment within 3 month liver resection . Patients group B anti-cancer therapy . Anti-virus supportive therapy available group .</brief_summary>
	<brief_title>Study Cytokine-induced Killer Cell ( CIK ) Treatment Patients After Resection Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion Criteria Male female patient &gt; 18 year age . Without prior anticancer therapy . Patients life expectancy least 12 week . Patients already radical resection HCC . Definition radical resection study : All tumor move , clean resection margin . Number tumor &lt; = 3 . Without tumor invasion main trunk first branch portal vein , hepatic duct , hepatic vein . No hepatic hilum lymphnode metastasis . No distance metastasis . Hepatocellular carcinoma histological diagnose . No major postoperative complication . Patients ECOG PS 0 , 1 . Cirrhotic status ChildPugh class A . The following laboratory parameter : Platelet count &gt; = 70 x 109/L Hemoglobin &gt; = 8.5 g/dL Albumin &gt; = 3.5 g/dL Total bilirubin &lt; = 25umol/L Alanine transaminase ( ALT ) AST &lt; = 2.5 x upper limit normal Serum creatinine &lt; = 1.5 x upper limit normal Prothrombin time ( PT ) &lt; = 3 second control . Patients give write informed consent . Exclusion Criteria Previous concurrent cancer distinct primary site histology HCC . History cardiac disease . Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . History organ allograft . Known suspected allergy investigational agent agent give association trial . Pregnant breastfeeding patient . Any condition unstable could jeopardize safety patient his/her compliance study . Excluded therapy medication , previous concomitant : Prior use anticancer treatment HCC , eg . chemotherapy , radiotherapy . Antiviral treatment allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>recurrent</keyword>
	<keyword>cytokine-induced killer cell</keyword>
</DOC>